[go: up one dir, main page]

RU2013131870A - METHOD FOR DETECTING AVAILABILITY, SEVERITY, RISK AND POSITION FOR RECIDIENTS, AND ALSO TREATMENT AND REACTION TO TREATMENT OF URINARY INFLAMMATION AND KITS FOR ITS DESCRIPTION - Google Patents

METHOD FOR DETECTING AVAILABILITY, SEVERITY, RISK AND POSITION FOR RECIDIENTS, AND ALSO TREATMENT AND REACTION TO TREATMENT OF URINARY INFLAMMATION AND KITS FOR ITS DESCRIPTION Download PDF

Info

Publication number
RU2013131870A
RU2013131870A RU2013131870/15A RU2013131870A RU2013131870A RU 2013131870 A RU2013131870 A RU 2013131870A RU 2013131870/15 A RU2013131870/15 A RU 2013131870/15A RU 2013131870 A RU2013131870 A RU 2013131870A RU 2013131870 A RU2013131870 A RU 2013131870A
Authority
RU
Russia
Prior art keywords
eosinophilic peroxidase
detecting
eosinophilic
peroxidase
sample
Prior art date
Application number
RU2013131870/15A
Other languages
Russian (ru)
Original Assignee
Павлов Владимир Игоревич
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Павлов Владимир Игоревич filed Critical Павлов Владимир Игоревич
Priority to RU2013131870/15A priority Critical patent/RU2013131870A/en
Priority to PCT/RU2014/000422 priority patent/WO2015005823A1/en
Publication of RU2013131870A publication Critical patent/RU2013131870A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5428—IL-10
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5437—IL-13
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/908—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

1. Способ обнаружения воспаления мочевыводящих путей у пациента, содержащий: а) обеспечение образца от пациента; и б) обнаружение в указанном образце экспрессии по меньшей мере одного из биомаркеров, выбранных из группы, содержащей ИЛ-33, ИЛ-13, ИЛ-10 и эозинофильную пероксидазу.2. Способ по п. 1, включающий обнаружение присутствия мРНК для ИЛ-33 и/или ИЛ-13 и/или ИЛ-10 и/или эозинофильной пероксидазы.3. Способ по п. 2, включающий взаимодействие указанных мРНК для ИЛ-33 и/или ИЛ-13, и/или ИЛ-10, и/или эозинофильной пероксидазы с зондом из нуклеиновой кислоты, комплементарным к указанной мРНК для ИЛ-33 и/или ИЛ-13, и/или ИЛ-10 и/или эозинофильной пероксидазы.4. Способ по п. 1, включающий обнаружение присутствия полипептидов ИЛ-33 и/или ИЛ-13 и/или ИЛ-10 и/или эозинофильной пероксидазы.5. Способ по п. 4, включающий взаимодействие указанных полипептидов ИЛ-33 и/или ИЛ-13 и/или ИЛ-10 и/или эозинофильной пероксидазы с антителом, специфичным к указанному полипептиду ИЛ-33 и/или ИЛ-13 и/или ИЛ-10 и/или эозинофильной пероксидазы и обнаружение связывания указанного антитела с указанным полипептидом ИЛ-33 и/или ИЛ-13 и/или ИЛ-10 и/или эозинофильной пероксидазы.6. Способ по п. 1, в котором испытуемым является человек.7. Способ по п. 1, где образец включает мочу, кровь, и/или клетки или ткань мочевого пузыря.8. Способ лечения обнаруженного в соответствии со способом по п. 1 воспаления мочевыводящих путей, включающий: а) обеспечение образца от исследуемого; б) обнаружение экспрессии ИЛ-33 и/или ИЛ-13 и/или ИЛ-10 и/или эозинофильной пероксидазы в указанном образце; в) на основании указанной экспрессии ИЛ-33 и/или ИЛ-13 и/или ИЛ-10 и/или эозинофильной пероксидазы подавление воспаления с пом1. A method for detecting inflammation of the urinary tract in a patient, comprising: a) providing a sample from the patient; and b) detecting in said sample expression of at least one of the biomarkers selected from the group consisting of IL-33, IL-13, IL-10 and eosinophilic peroxidase. 2. A method according to claim 1, comprising detecting the presence of mRNA for IL-33 and / or IL-13 and / or IL-10 and / or eosinophilic peroxidase. 3. The method of claim 2, comprising reacting said mRNA for IL-33 and / or IL-13 and / or IL-10 and / or eosinophilic peroxidase with a nucleic acid probe complementary to said mRNA for IL-33 and / or IL-13, and / or IL-10 and / or eosinophilic peroxidase. 4. A method according to claim 1, comprising detecting the presence of IL-33 and / or IL-13 and / or IL-10 and / or eosinophilic peroxidase polypeptides. The method of claim 4, comprising reacting said IL-33 and / or IL-13 and / or IL-10 and / or eosinophilic peroxidase polypeptides with an antibody specific for said IL-33 and / or IL-13 and / or IL -10 and / or eosinophilic peroxidase and detecting binding of the indicated antibody to the indicated IL-33 and / or IL-13 and / or IL-10 and / or eosinophilic peroxidase polypeptide. 6. The method of claim 1, wherein the test person is a human. The method of claim 1, wherein the sample includes urine, blood, and / or cells or tissue of the bladder. A method of treating an inflammation of the urinary tract detected in accordance with the method of claim 1, comprising: a) providing a sample from the subject; b) detecting the expression of IL-33 and / or IL-13 and / or IL-10 and / or eosinophilic peroxidase in the specified sample; c) based on the indicated expression of IL-33 and / or IL-13 and / or IL-10 and / or eosinophilic peroxidase, suppression of inflammation with

Claims (14)

1. Способ обнаружения воспаления мочевыводящих путей у пациента, содержащий: а) обеспечение образца от пациента; и б) обнаружение в указанном образце экспрессии по меньшей мере одного из биомаркеров, выбранных из группы, содержащей ИЛ-33, ИЛ-13, ИЛ-10 и эозинофильную пероксидазу.1. A method for detecting inflammation of the urinary tract in a patient, comprising: a) providing a sample from the patient; and b) detecting in said sample expression of at least one of the biomarkers selected from the group consisting of IL-33, IL-13, IL-10 and eosinophilic peroxidase. 2. Способ по п. 1, включающий обнаружение присутствия мРНК для ИЛ-33 и/или ИЛ-13 и/или ИЛ-10 и/или эозинофильной пероксидазы.2. The method of claim 1, comprising detecting the presence of mRNA for IL-33 and / or IL-13 and / or IL-10 and / or eosinophilic peroxidase. 3. Способ по п. 2, включающий взаимодействие указанных мРНК для ИЛ-33 и/или ИЛ-13, и/или ИЛ-10, и/или эозинофильной пероксидазы с зондом из нуклеиновой кислоты, комплементарным к указанной мРНК для ИЛ-33 и/или ИЛ-13, и/или ИЛ-10 и/или эозинофильной пероксидазы.3. The method according to p. 2, comprising the interaction of these mRNAs for IL-33 and / or IL-13, and / or IL-10, and / or eosinophilic peroxidase with a probe from a nucleic acid complementary to the specified mRNA for IL-33 and / or IL-13, and / or IL-10 and / or eosinophilic peroxidase. 4. Способ по п. 1, включающий обнаружение присутствия полипептидов ИЛ-33 и/или ИЛ-13 и/или ИЛ-10 и/или эозинофильной пероксидазы.4. The method according to p. 1, comprising detecting the presence of IL-33 and / or IL-13 and / or IL-10 and / or eosinophilic peroxidase polypeptides. 5. Способ по п. 4, включающий взаимодействие указанных полипептидов ИЛ-33 и/или ИЛ-13 и/или ИЛ-10 и/или эозинофильной пероксидазы с антителом, специфичным к указанному полипептиду ИЛ-33 и/или ИЛ-13 и/или ИЛ-10 и/или эозинофильной пероксидазы и обнаружение связывания указанного антитела с указанным полипептидом ИЛ-33 и/или ИЛ-13 и/или ИЛ-10 и/или эозинофильной пероксидазы.5. The method according to p. 4, comprising the interaction of these polypeptides IL-33 and / or IL-13 and / or IL-10 and / or eosinophilic peroxidase with an antibody specific for the specified polypeptide IL-33 and / or IL-13 and / or IL-10 and / or eosinophilic peroxidase and the detection of binding of the indicated antibodies to the specified polypeptide of IL-33 and / or IL-13 and / or IL-10 and / or eosinophilic peroxidase. 6. Способ по п. 1, в котором испытуемым является человек.6. The method according to p. 1, in which the subject is a person. 7. Способ по п. 1, где образец включает мочу, кровь, и/или клетки или ткань мочевого пузыря.7. The method of claim 1, wherein the sample includes urine, blood, and / or cells or tissue of the bladder. 8. Способ лечения обнаруженного в соответствии со способом по п. 1 воспаления мочевыводящих путей, включающий: а) обеспечение образца от исследуемого; б) обнаружение экспрессии ИЛ-33 и/или ИЛ-13 и/или ИЛ-10 и/или эозинофильной пероксидазы в указанном образце; в) на основании указанной экспрессии ИЛ-33 и/или ИЛ-13 и/или ИЛ-10 и/или эозинофильной пероксидазы подавление воспаления с помощью моноклональных антител и/или растворимых рецепторов и/или ингибиторов протеаз против, соответственно, полипептида или гена ИЛ-33 и/или ИЛ-13 и/или ИЛ-10 и/или эозинофильной пероксидазы.8. A method of treating an inflammation of the urinary tract detected in accordance with the method of claim 1, comprising: a) providing a sample from the subject; b) detecting the expression of IL-33 and / or IL-13 and / or IL-10 and / or eosinophilic peroxidase in the specified sample; c) based on the indicated expression of IL-33 and / or IL-13 and / or IL-10 and / or eosinophilic peroxidase, suppression of inflammation with monoclonal antibodies and / or soluble receptors and / or protease inhibitors against, respectively, the IL polypeptide or gene -33 and / or IL-13 and / or IL-10 and / or eosinophilic peroxidase. 9. Способ по п. 8, дополнительно включающий определение ИЛ-33 и лактатдегидрогеназы (ЛДГ) у испытуемого и лечение испытуемого на основании дифференциального диагноза рака и инфекции мочевыводящих путей.9. The method of claim 8, further comprising determining IL-33 and lactate dehydrogenase (LDH) in the subject and treating the subject based on a differential diagnosis of cancer and urinary tract infection. 10. Набор для описания в испытуемом обнаруженного в соответствии со способом по п. 1 воспаления мочевыводящих путей, включающий: а) реагент, обладающий способностью специфически обнаруживать присутствие или отсутствие экспрессии ИЛ-33 и/или ИЛ-13 и/или ИЛ-10 и/или эозинофильной пероксидазы; и б) инструкцию по использованию указанного набора для описания воспаления мочевыводящих путей в указанном испытуемом.10. A kit for describing in a test subject a urinary tract inflammation detected in accordance with the method of claim 1, comprising: a) a reagent capable of specifically detecting the presence or absence of expression of IL-33 and / or IL-13 and / or IL-10 and / or eosinophilic peroxidase; and b) instructions for using the indicated kit to describe urinary tract inflammation in the test subject. 11. Набор по п. 10, в котором указанный реагент включает в себя зонд из нуклеиновой кислоты, комплементарный к ИЛ-33 и/или ИЛ-13 и/или ИЛ-10 и/или эозинофильной пероксидазы мРНК.11. The kit of claim 10, wherein said reagent includes a nucleic acid probe complementary to IL-33 and / or IL-13 and / or IL-10 and / or eosinophilic peroxidase mRNA. 12. Набор по п. 10, в котором указанный реагент включает в себя антитело, специфически связывающееся с полипептидом ИЛ-33 и/или ИЛ-13 и/или ИЛ-10 и/или эозинофильной пероксидазы.12. The kit of claim 10, wherein said reagent includes an antibody specifically binding to an IL-33 and / or IL-13 and / or IL-10 polypeptide and / or eosinophilic peroxidase. 13. Набор по п. 10, дополнительно включающий антитело, специфически связывающееся с лактатдегидрогеназой (ЛДГ), и нуклеотидный зонд, специфически узнающий мРНК лактатдегидрогеназы (ЛДГ).13. The kit of claim 10, further comprising an antibody specifically binding to lactate dehydrogenase (LDH), and a nucleotide probe specifically recognizing lactate dehydrogenase mRNA (LDH). 14. Набор по пункту 10, дополнительно включающий в себя опросник для испытуемого на наличие боли. 14. The kit of claim 10, further comprising a questionnaire for the subject for pain.
RU2013131870/15A 2013-07-11 2013-07-11 METHOD FOR DETECTING AVAILABILITY, SEVERITY, RISK AND POSITION FOR RECIDIENTS, AND ALSO TREATMENT AND REACTION TO TREATMENT OF URINARY INFLAMMATION AND KITS FOR ITS DESCRIPTION RU2013131870A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
RU2013131870/15A RU2013131870A (en) 2013-07-11 2013-07-11 METHOD FOR DETECTING AVAILABILITY, SEVERITY, RISK AND POSITION FOR RECIDIENTS, AND ALSO TREATMENT AND REACTION TO TREATMENT OF URINARY INFLAMMATION AND KITS FOR ITS DESCRIPTION
PCT/RU2014/000422 WO2015005823A1 (en) 2013-07-11 2014-06-06 Methods for detecting, treating and preventing urinary tract inflammation/infection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2013131870/15A RU2013131870A (en) 2013-07-11 2013-07-11 METHOD FOR DETECTING AVAILABILITY, SEVERITY, RISK AND POSITION FOR RECIDIENTS, AND ALSO TREATMENT AND REACTION TO TREATMENT OF URINARY INFLAMMATION AND KITS FOR ITS DESCRIPTION

Publications (1)

Publication Number Publication Date
RU2013131870A true RU2013131870A (en) 2015-01-20

Family

ID=52280356

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013131870/15A RU2013131870A (en) 2013-07-11 2013-07-11 METHOD FOR DETECTING AVAILABILITY, SEVERITY, RISK AND POSITION FOR RECIDIENTS, AND ALSO TREATMENT AND REACTION TO TREATMENT OF URINARY INFLAMMATION AND KITS FOR ITS DESCRIPTION

Country Status (2)

Country Link
RU (1) RU2013131870A (en)
WO (1) WO2015005823A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2115124C1 (en) * 1994-05-17 1998-07-10 Михаил Иосифович Коган Method of diagnosis of pyelonephritis acute stage
RU2153672C1 (en) * 1999-10-22 2000-07-27 Московский областной научно-исследовательский клинический институт Method for performing differential diagnosis of inflammatory processes in male urogenital paths
RU2215534C2 (en) * 2002-01-08 2003-11-10 Государственное унитарное предприятие "Иммунопрепарат" Method for treatment of inflammatory diseases of organs of urinary system
GB0423974D0 (en) * 2004-10-28 2004-12-01 Ares Trading Sa Proteins
CN101512008B (en) * 2006-09-08 2015-04-01 艾伯维巴哈马有限公司 Interleukin-13 binding proteins

Also Published As

Publication number Publication date
WO2015005823A1 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
Chen et al. Saliva-based COVID-19 detection: A rapid antigen test of SARS-CoV-2 nucleocapsid protein using an electrical-double-layer gated field-effect transistor-based biosensing system
Worasith et al. Advances in the diagnosis of human opisthorchiasis: development of Opisthorchis viverrini antigen detection in urine
WO2010038974A3 (en) Composition and kit for diagnosing immunoglobulin a nephropathy and tgbm nephropathy
NZ601022A (en) Diagnosis and treatment of cancer using anti-ereg antibody
NZ599105A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2015517801A5 (en)
JP2017524130A5 (en)
RU2014114838A (en) WAYS OF CONTROL OF SUSCEPTIBILITY OF ANTI-SMAD7 THERAPY
MY162697A (en) Methods, devices and kits for detecting or monitoring acute kidney injury
EP2569635A4 (en) METHODS OF DIAGNOSING AND TREATING ENCEPHALITY OR EPILEPSY
RU2018108831A (en) BIOMARKERS FOR TREATMENT OF Focal Alopecia
RU2014122607A (en) METHODS FOR DETERMINING A PATIENT'S SUSCEPTIBILITY TO IN-HOSPITAL INFECTION AND FORMING A FORECAST OF SEPTIC SYNDROME DEVELOPMENT
WO2020148590A1 (en) Nourin molecular biomarkers
EP3194963A1 (en) Compositions and methods for detecting anti-endothelial cell antibodies in allograft rejection
Sun et al. Downregulation of microRNA‐101‐3p participates in systemic lupus erythematosus progression via negatively regulating HDAC9
TW201621318A (en) Skin viscoelastic markers and their utilization
JP2006311860A5 (en)
CN101937001A (en) Kit for diagnosing acute rejection after kidney transplantation
KR20170093141A (en) Arteriosclerosis and cancer detection method using deoxyhypusine synthase gene as indicator
RU2013131870A (en) METHOD FOR DETECTING AVAILABILITY, SEVERITY, RISK AND POSITION FOR RECIDIENTS, AND ALSO TREATMENT AND REACTION TO TREATMENT OF URINARY INFLAMMATION AND KITS FOR ITS DESCRIPTION
WO2014011416A3 (en) Cell-based assay for neutralizing antibodies
JP2015169608A (en) Cancer testing methods
RU2014114138A (en) METHOD (OPTIONS) AND KIT FOR DIAGNOSTIC OF URINARY INFECTIONS, METHOD OF TREATMENT AND PREPARATION OF URINARY INFECTIONS
JP2023156159A5 (en)
Otoni et al. Chemokine profile in the sera and urine of patients with schistosomal glomerulopathy

Legal Events

Date Code Title Description
HE9A Changing address for correspondence with an applicant
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20151028